|
|
News Breaks
|
July 6, 2011
|
| 08:48 EDT |  | CBM |
| theflyonthewall.com: | Cambrex, Tillotts enter development/commercialization agreement | | Cambrex and Tillotts Pharma AG announced they have entered into a Development and Commercialization Agreement for a proprietary mesalamine-based, or 5-ASA, technology for use in the treatment of Inflammatory Bowel Disease, or IBD. Under the terms of the agreement, Tillotts has acquired from Cambrex worldwide exclusive rights to develop and commercialize drug products based on the proprietary 5-ASA-based technology in exchange for developmental, regulatory and IP milestone payments as well as royalties. Cambrex previously acquired the exclusive rights to this technology from PLx Pharma Inc. :theflyonthewall.com |
|
|
News For CBM From The Last 14 Days Check below for free stories on CBM the last two weeks.
| Sign up for a free trial to see the rest of the stories you've been missing. |
There are no results for these search parameters.
|
|
|
|
